Article Text
Education in Heart
Clinical pharmacology
Triple antithrombotic therapy after ACS and PCI in patients on chronic oral anticoagulation: update
Statistics from Altmetric.com
Footnotes
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests Speaker’s and consulting fees from AstraZeneca, Bayer and Sanofi-Aventis.
Patient consent Not required.
Provenance and peer review Commissioned; externally peer reviewed.
Author note References that include an asterisk (*) are considered to be key references.